Search Results for "Cephalexin Bioequivalence"
Original Source: Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules
A single dose, two treatments (two cephalexin capsules brands), two sequences, cross-over design was used with a washout of 7 days between the two study periods. Treatment groups balanced with the same number of healthy volunteers who were randomly (in two strata: male and female) assigned to the study drug administration sequences.
Matching Channels
None
Matching News
FDA Approving More ANDAs That Use Novel Bioequivalence Methods
OGD officials report on the progress being made in approving generic drugs using more novel and science-based bioequivalence methods than in the past. Officials impart tips on how to submit review-rea...
RedHill bioequivalence trial with RHB-103 meets specified endpoints
RedHill Biopharma has announced positive results from a pivotal bioequivalence trial with RHB-103, an oral thin-film formulation of Rizatriptan for the treatment of acute migraine.
Generic Bupropion XL Reevaluation Running Behind Schedule
FDA has received data from just one of four bioequivalence studies of 300 mg bupropion extended-release generics it requested by March from sponsors following Impax/Teva’s withdrawal of their generi...
Azaya Therapeutics commences ATI-0918 bioequivalence study in ovarian cancer
Azaya Therapeutics, Inc. today announced the initiation of a bioequivalence study of ATI-0918 in patients with ovarian cancer.
Bioequivalence Testing Is First Step In China’s Pharma Industry Upgrade – RDPAC
Time is tight for China to complete an ambitious generic bioequivalence testing schedule, and the stakes couldn’t be higher for the industry, a top executive of the leading trade association in Chin...
Type: Review PaperFixed-dose combination (FDC) products are becoming a popular treatment option because of increased patient compliance and convenience, improved clinical effectiveness, and reduced co...
EPIRUS’ BOW-015 achieves bioequivalence to Remicade in a single dose comparator trial
EPIRUS Biopharmaceuticals, Inc., formerly known as fourteen22 Inc, announced that its lead asset, BOW-015, achieved bioequivalence to Remicade in a single dose comparator trial.
RedHill Biopharma Announces a Successful Pivotal Bioequivalence Trial with RHB-103 for the ...
The Trial Met its Specified Endpoints and Demonstrated Bioequivalence Between RedHill Biopharma's Oral Thin-Film RHB-103 and Merck & Co.'s Leading Rizatriptan Drug with Annual Sales Exceeding...
Matching PubMed Articles
Selection of CMY-2 producing Escherichia coli in the faecal flora of dogs treated with cephalexin.
Cephalexin is a first generation cephalosporin commonly used in dogs for treatment of pyoderma. The objective of this study was to evaluate the in vivo effects of cephalexin on selection of Escherichi...
The pharmacokinetic profile and bioavailability of a long-acting formulation of cephalexin after intramuscular administration to cats was investigated. Single intravenous (cephalexin lysine salt) and...
Pharmacodynamic bioequivalence testing.
What is known and Objective: The assessment of bioequivalence of drugs intended for local action/targeted delivery and with poor systemic absorption presents unique challenges. Approaches such as p...
Coralline calcium-hydroxyapatite and calcium carbonate from Porites Porites coral were added to a polymeric matrix based on polyvinyl acetate (POVIAC(®)), to obtain a novel bone substitute composite...
Bioequivalence for Topical Products-An Update.
With the exception of topical glucocorticoids, demonstrating bioequivalence between generic and reference topical products entails conducting clinical end-point trials which are both lengthy and expen...
